Mackenzie Financial
MRTX

Mackenzie Financial’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Mackenzie Financial’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,550
Closed -$660K – 1341
2018
Q4 		$660K Buy
+15,550
New +$620K ﹤0.01% 879

Other funds holding MRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Mackenzie Financial's MRTX Position: Q1 2019 in Review

Mackenzie Financial sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2019, closing a stake of 15,550 shares — an estimated $660K sold.

Mackenzie Financial first reported a position in MRTX in Q4 2018 and held it in 1 quarter. The position peaked at $660K in Q4 2018. 159 funds tracked by Wall St. Rank hold MRTX as of Q1 2019.

  • Mackenzie Financial reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Mackenzie Financial sold 15,550 Mirati Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $660K.
  • Mackenzie Financial first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Mackenzie Financial's Mirati Therapeutics, Inc. Common Stock position peaked at $660K in Q4 2018.
  • 159 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Mackenzie Financial's 13F filing for Q1 2019, filed 15 May 2019.